April 2026 Data (May Edition)

Section A: The Themes Hidden in April's Lobbying Data

Spike in Pharmaceutical Lobbying as EU Health Package Rolls Out

April 2026 saw an intensified lobbying effort from pharmaceutical manufacturers such as AstraZeneca PLC, Bristol-Myers Squibb Company, and the European Federation of Pharmaceutical Industries and Associations, coinciding with the European Commission's launch of the EU Health Package and Biotech Act. These new rules aim to speed clinical trial approvals and incentivize advanced therapies, attracting focused input from pharma lobbyists in meetings with Comm Varhelyi (Health and Animal Welfare) and the Direct. Gen. Health and Animal Welfare, keen to shape implementation.

📎 EU Health Package Advances Biotech Reforms and Streamlines Clinical Trials for 2026 · European Biotech Act

Veterinary Sector Prepares for July Regulation Overhaul

Lobbying by organisations such as Access VetMed, Federation of Veterinarians of Europe, AnimalhealthEurope, and the Association of Veterinary Consultants, engaging with the Directorate-General for Health and Animal Welfare, surged in April, coinciding with industry preparations for stricter EU good manufacturing practice standards taking effect in July 2026. The regulatory overhaul is driving industry engagement to address compliance and operational concerns before enforcement begins.

📎 Implementation of Regulation 2019/6 · New EU GMP Requirements for Veterinary Medicinal Products: What Companies should consider before 16 July 2026

Senior & Disability Social Work Groups Engage on Windsor Framework Implementation

Spring 2026 featured continued civic society consultations under the EU-UK Withdrawal Agreement's Windsor Framework, during which groups representing senior and disability social work, including the Royal National Institute of Blind People in dialogue with the Secretariat-General and Social Services Europe engaging with EVP Minzatu, voiced concerns about Brexit's effects on medicine supply and cross-border care. The uptick in social care lobbying, reflected by contributions from the International Federation of Red Cross and Red Crescent Societies and Association of the European Self-Care Industry, aligns with ongoing dialogue on regulatory impacts for vulnerable populations in Northern Ireland.

📎 The Windsor Framework · Brexit and Beyond: The Windsor Framework

Section B: Lobbying Activity by Industry

This section compares, by industry, the lobbying activity with the European Commission last month to its historical average.

Industry Lobbying Activity, April 2026

In April 2026, 7 industries from this sector were active in lobbying meetings with the European Commission, led by Pharmaceutical preparations.

Industries running notably above their historical average this month include Veterinary Services, Basic pharmaceutical products, and Senior & Disability Social Work.

On the quieter side, Pharmaceutical preparations, Other Human Health, Medical and Dental Instruments, and Other Social Work w/o Accommodation saw notably less lobbying activity than their historical average.

Section C: Lobbying by Industry for the Past Year

To contextualize Section B, this chart shows the residual trajectory of the same top industries from Section B over the past 12 months — the deviation from what would be expected after accounting for seasonal patterns and the overall trend. Persistent above-zero values indicate sustained over-activity; persistent below-zero values indicate sustained quiet periods.

Industry Lobbying Residuals, April 2026

This chart shows the 7 industries in this sector with the largest deviations from expected lobbying activity in April 2026. Positive values run above their seasonal trend, negative values below.

Other Human Health, Senior & Disability Social Work, Medical and Dental Instruments, Other Social Work w/o Accommodation, and Pharmaceutical preparations saw lobbying notably below expected levels this month.

Section D: Lobbying Activity by Organization

In this section, we see the organizations with the most unusual lobbying behavior last month, defined by either unusually high or unusually low lobbying activity.

Organization Lobbying Activity, April 2026

In April 2026, 30 organizations from this sector took part in 22 lobbying meetings with the European Commission.

The organizations with the most notable increases in lobbying activity this month include Medecins Sans Frontieres International.

On the quieter side, Merck Sharp & Dohme Europe Belgium SRL, Gates Foundation, MedTech Europe, EuropaBio, and Merck saw notably less lobbying activity than usual.

New to the sector's lobbying records this month: Royal National Institute of Blind People.

Section E: Lobbying of Government Institutions in the Past Month

Every lobbying meeting takes place with one of two types of European Commission body: a Commissioner's cabinet (political staff) or a Directorate-General (the civil service). This section shows the organisation-to-institution pairings with the most unusual lobbying activity last month, defined by the largest absolute difference between this month's meeting count and the pair's 12-month rolling average.

Lobbying of Commission Institutions, April 2026 vs 12-Month Avg

In April 2026, 30 organisations from this sector met with 13 Commission bodies across 22 meetings — split across 5 Commissioner cabinets and 8 Directorates-General.

Notable increases in lobbying activity this month include European Federation of Pharmaceutical Industries and Associations with Comm Varhelyi (Health and Animal Welfare).

On the quieter side, Merck Sharp & Dohme Europe Belgium SRL with Comm Varhelyi (Health and Animal Welfare) saw notably less lobbying activity than their historical average.

Section F: Organization Lobbying by Subject in the Past Month

This section shows the organisation-to-subject pairings with the most unusual lobbying activity last month. Subjects are classified from each meeting's title text into one of 19 EU policy areas. A meeting covering multiple topics counts toward each of them.

Lobbying by Subject, April 2026 vs 12-Month Avg

In April 2026, 30 organisations from this sector lobbied on 5 policy topics across 22 meetings. Meetings may touch multiple topics, so subject totals can exceed total meetings.

Topics with notably elevated lobbying activity this month include European Federation of Pharmaceutical Industries and Associations on Healthcare.

On the quieter side, Merck Sharp & Dohme Europe Belgium SRL on Healthcare, International Federation of Red Cross and Red Crescent Societies on Foreign Affairs, and MedTech Europe on Healthcare saw notably less lobbying activity than their historical average.

Section G: Most-Lobbied Officials

This section lists the most-frequent lobbying touchpoints between this sector's organisations and individual European Commission officials last month, compared to each pairing's average over the past year.

Most-Lobbied Officials, April 2026

In April 2026, 24 European Commission officials took part in 22 meetings with this sector's lobbyists.

The most-frequent meetings this month were European Federation of Pharmaceutical Industries and Associations and Oliver Varhelyi + 4 others at Comm Varhelyi (Health and Animal Welfare), PIERRE FABRE SA and Oliver Varhelyi + 1 other at Comm Varhelyi (Health and Animal Welfare), MedTech Europe and Oliver Varhelyi + 4 others at Comm Varhelyi (Health and Animal Welfare), MEDICINES FOR EUROPE and Oliver Varhelyi + 4 others at Comm Varhelyi (Health and Animal Welfare), and Ultragenyx Europe Gmbh and Oliver Varhelyi at Comm Varhelyi (Health and Animal Welfare).

Most activity came from Cabinet members (44 meetings), followed by Commissioner (11) and Head of Unit (11).